Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

419
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
419
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

182
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
182
Neural Regulation01:37

Neural Regulation

39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

223
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
223

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating smiling asymmetries in Parkinson's disease through the whistle-smile reflex.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Neurodegenerative diseases and environmental risk factors: an overview of the available scientific evidence.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Stereotypies misdiagnosed as functional neurological disorder in late-onset Niemann-Pick C.

Parkinsonism & related disorders·2026
Same author

Genetic and environmental risk factors of Parkinsonism.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Functional Neurological Disorder during Foscarbidopa/Foslevodopa Infusion in PRKN-Associated Parkinsonism.

Movement disorders clinical practice·2026
Same author

Outcomes predictors in patients with basilar artery occlusion and mild deficits, treated with mechanical thrombectomy: A multicenter retrospective observational study.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same journal

Advances in CSF1R-related disorder: novel mutations, dopaminergic imaging, and overcoming underdiagnosis.

Neurologia i neurochirurgia polska·2026
Same journal

Electrophysiological markers of subclinical central nervous system involvement in patients with non-small-cell lung cancer without brain metastases.

Neurologia i neurochirurgia polska·2026
Same journal

Highlighting the CSF1R mutational spectrum: c.2549C>T variant in late-onset leukoencephalopathy mimicking multiple sclerosis.

Neurologia i neurochirurgia polska·2026
Same journal

Sacroiliac joint manipulation for low back and radicular pain: outcomes in a 100-patient single-center cohort.

Neurologia i neurochirurgia polska·2026
Same journal

Beyond leukodystrophy: parkinsonism and microglial failure in CSF1R p.Ile794Thr.

Neurologia i neurochirurgia polska·2026
Same journal

Genetic screening for CSF1R variants in patients with dementia, parkinsonism, and multiple sclerosis.

Neurologia i neurochirurgia polska·2026
See all related articles

Related Experiment Video

Updated: May 24, 2025

The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

10.4K

Do Parkinson's Disease clinical subtypes really exist?

Marta Filidei1, Luca Marsili2, Carlo Colosimo3

  • 1Department of Neurology, Santa Maria University Hospital, Terni, Italy.

Neurologia I Neurochirurgia Polska
|March 3, 2025
PubMed
Summary
This summary is machine-generated.

Parkinson's Disease (PD) subtypes lack biological support, hindering prognosis and treatment prediction. Future research should focus on a biological classification aided by biomarkers to better understand PD aetiology.

Keywords:
Parkinson’s Diseasealpha-synucleinbiomarkersdiagnostic criteria

More Related Videos

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.5K
Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
08:33

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

8.2K

Related Experiment Videos

Last Updated: May 24, 2025

The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

10.4K
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.5K
Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
08:33

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

8.2K

Area of Science:

  • Neurology
  • Neuroscience
  • Medical Research

Background:

  • Parkinson's Disease (PD) exhibits significant heterogeneity in clinical presentation, progression, and treatment response.
  • This variability suggests the existence of distinct clinical subtypes.
  • Previous subtyping efforts have identified 'benign' and 'malignant' subtypes based on clinical features and limited biomarkers.

Purpose of the Study:

  • To review existing literature on Parkinson's Disease subtyping.
  • To examine proposed biomarkers for biological classification.
  • To outline the role of genetics and pathology in PD classification.

Main Methods:

  • Literature review of Parkinson's Disease subtyping studies.
  • Analysis of proposed biomarkers (fluid, neuroimaging, neurophysiological).
  • Examination of genetic and pathological factors in PD classification.

Main Results:

  • Current clinical subtypes of PD lack robust biological validation.
  • Existing subtyping does not reliably predict prognosis or treatment response.
  • Biomarkers are crucial for advancing towards a biological classification of PD.

Conclusions:

  • Clinical subtyping of Parkinson's Disease has not elucidated its aetiology.
  • A shift towards a biological classification is needed, leveraging advances in biomarkers.
  • Future research should focus on biological markers to overcome limitations of clinical diagnosis.